shutterstock_528642268-1
31 July 2019AmericasSarah Morgan

Alkermes settles with Amneal over opioid dependence treatment

Biopharmaceutical company  Alkermes has entered into a settlement and licence agreement with generic maker  Amneal Pharmaceuticals to resolve an inter partes review (IPR).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
Americas
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.

More on this story

Big Pharma
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
Americas
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.

More on this story

Big Pharma
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
Americas
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.